表达野生型和突变型HPV16-E7重组痘苗病毒诱发的抗肿瘤免疫反应  

The recombinant vaccinia viruses expressing HPV type 16 wild or mutant E7 protein elicit immunity against tumor cells in mice

作　　者：职慧军[1] 韩立群[1] 任皎[1] 田厚文[1] 骆卫锋[1] 梁雨[1] 阮力[1] 

机构地区：[1]中国预防医学科学院病毒学研究所遗传免疫研究室,北京100052

出　　处：《中华实验和临床病毒学杂志》2001年第3期222-225,共4页Chinese Journal of Experimental and Clinical Virology

基　　金：国家"九五"攻关重点项目资助基金 (96 90 6 0 1 11)

摘　　要：目的　选出适合于治疗性疫苗研制的HPV16E7突变基因。方法　对表达野生型和突变型E7蛋白的重组痘苗病毒所诱发的细胞免疫反应和抗肿瘤活性进行比较研究。结果　表达突变型ME7 1(2 4G2 6G)的重组痘苗病毒VmE7 1与表达野生型E7的VwE7相同 ,可诱发特异性抗体和CTL的产生 ,明显推迟成瘤时间并且保护部分小鼠抵抗肿瘤细胞的攻击 ;而表达突变型ME7 2(2 4G2 6G91G)的重组痘苗病毒VmE7 2免疫小鼠后难以有效的激发细胞免疫反应 ,在抗肿瘤移植实验中也不具明显的免疫保护作用。结论　E7突变基因ME7 1可作为候选基因用于HPV16治疗性疫苗的研制。Objective To select mutants of HPV 16 E7 suitable for vaccine development.Methods Several recombinant vaccinia viruses (VwE7,VmE7 1,and VmE7 2)expressing wild E7 or its mutants,ME7 1 (24G26G) and ME7 2(24G26G91G) respectively,were employed to study their antigenicity and anti tumor activity.Results Both VmE7 1 and VwE7 could elicit cytotoxic T lymphocytes(CTL)and protect mice against tumor cells challenge,but VmE7 2 could not induce the immune reactions compared with VmE7 1 and VwE7.Conclusion It suggested that ME7 1 could be used to develop a therapeutic vaccine for cervical cancer.

关 键 词：乳头状瘤病毒 宫颈肿瘤 疫苗 插入诱变 

分 类 号：R730.3[医药卫生—肿瘤]